150 related articles for article (PubMed ID: 10506395)
1. [Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
Arntz HR; Wunderlich W; Schnitzer L; Stern R; Fischer F; Agrawal R; Linderer T; Schultheiss HP
Z Kardiol; 1999 Aug; 88(8):582-90. PubMed ID: 10506395
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
Arntz HR; Agrawal R; Wunderlich W; Schnitzer L; Stern R; Fischer F; Schultheiss HP
Am J Cardiol; 2000 Dec; 86(12):1293-8. PubMed ID: 11113401
[TBL] [Abstract][Full Text] [Related]
3. [Lipid intervention and coronary heart disease in men less than 56 years of age. The Coronary Intervention Study: CIS].
Rensing UF; Bestehorn HP; Roskamm H; Petersen J; Betz P; Spinder M; Benesch L; Schemeitat K; Blümchen G; Claus J; Wieland H; Böcker JF; Neiss A; Stiepel E; Mathes P; Kappenberger L; Braunagel K; Peters K; Meister G; Samek L; Schuon J; Leimenstoll B; Kiefer H
Z Kardiol; 1999 Apr; 88(4):270-82. PubMed ID: 10408031
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study.
Saito Y; Shirai K; Sasaki N; Shinomiya M; Yoshida S;
J Atheroscler Thromb; 2002; 9(2):99-108. PubMed ID: 12236319
[TBL] [Abstract][Full Text] [Related]
6. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
Sacks FM; Moyé LA; Davis BR; Cole TG; Rouleau JL; Nash DT; Pfeffer MA; Braunwald E
Circulation; 1998 Apr; 97(15):1446-52. PubMed ID: 9576424
[TBL] [Abstract][Full Text] [Related]
7. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
Cohen JD; Drury JH; Ostdiek J; Finn J; Babu BR; Flaker G; Belew K; Donohue T; Labovitz A
Am Heart J; 2000 Apr; 139(4):734-8. PubMed ID: 10740160
[TBL] [Abstract][Full Text] [Related]
8. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
[TBL] [Abstract][Full Text] [Related]
9. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
[TBL] [Abstract][Full Text] [Related]
10. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.
Pfeffer MA; Sacks FM; Moyé LA; East C; Goldman S; Nash DT; Rouleau JR; Rouleau JL; Sussex BA; Theroux P; Vanden Belt RJ; Braunwald E
J Am Coll Cardiol; 1999 Jan; 33(1):125-30. PubMed ID: 9935018
[TBL] [Abstract][Full Text] [Related]
11. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
[TBL] [Abstract][Full Text] [Related]
12. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
14. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
[TBL] [Abstract][Full Text] [Related]
15. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
[TBL] [Abstract][Full Text] [Related]
16. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT).
Koizumi J; Shimizu M; Miyamoto S; Origasa H; Mabuchi H
J Atheroscler Thromb; 2002; 9(5):251-9. PubMed ID: 12409635
[TBL] [Abstract][Full Text] [Related]
17. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
[TBL] [Abstract][Full Text] [Related]
18. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Schiel R; Bambauer R; Müller UA
Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
Hunninghake DB
Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
[TBL] [Abstract][Full Text] [Related]
20. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years.
Simons LA; Nestel PJ; Clifton P; Janus ED; Simons J; Parfitt A
Med J Aust; 1992 Nov; 157(9):584-9. PubMed ID: 1406416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
